| Powder: | Yes |
|---|---|
| Customized: | Customized |
| Certification: | GMP, HSE, ISO 9001, USP, BP |
| Suitable for: | Adult |
| State: | Powder |
| Purity: | >99% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier
Dapagliflozin (ForxigaTM) is a new type of anti-diabetic drug jointly developed by Bristol-Myers Squibb and AstraZeneca. It was approved for marketing by the European Medicines Agency Chemicalbook (EMA) on November 12, 2012. It is the first SGLT2 inhibitor approved to be marketed for the treatment of type 2 diabetes. It can be used as an important choice in the treatment of diabetes, and is suitable for use as an auxiliary diet and exercise to improve blood sugar control in adults with type 2 diabetes.
Dapagliflozin is a drug used to treat type 2 diabetes.It was developed by Bristol-Myers Squibb in partnership with AstraZeneca.Although dapagliflozin's method of action would operate on both types of diabetes and other conditions resulting in hyperglycemia, the current clinical trials specifically exclude participants with type 1 diabetes
| Item | Test Standard | Testing Result | |
| Assay | 99% | Complies | |
| Apperence | White Powder | Complies | |
| Particle Size | 100% pass 80 mesh | Complies | |
| Oder | Characteristic | Complies | |
| Taste | Characteristic | Complies | |
| Loss on Drying | ≤5.0% | 2.20% | |
| Residue on Ignition | ≤0.1% | 0.05% | |
| Residual | ≤0.1% | Complies | |
| Residual Ethanol | ≤0.5% | Complies | |
| Heave Mentals | ≤10ppm | Complies | |
| Na | ≤0.1% | <0.1% | |
| Pb | ≤3 ppm | Complies | |
| Total Plate | <1000CFU/g | Complies | |
| Yeast & Mold | <100 CFU /g | Complies | |
| E. Coli | Negative | Complies | |
| Salmonella | Negative | Complies | |
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}